PDBsum entry 3bwj

Go to PDB code: 
protein ligands links
Transferase/transferase inhibitor PDB id
Protein chain
341 a.a. *
ARX ×2
Waters ×175
* Residue conservation analysis
PDB id:
Name: Transferase/transferase inhibitor
Title: Complex of pka with the bisubstrate protein kinase inhibitor compound arc-1034
Structure: Camp-dependent protein kinase, alpha-catalytic su chain: a. Synonym: pka c-alpha. Engineered: yes
Source: Bos taurus. Bovine. Organism_taxid: 9913. Gene: prkaca. Expressed in: escherichia coli. Expression_system_taxid: 562.
2.30Å     R-factor:   0.201     R-free:   0.249
Authors: D.Lavogina,N.Koenig,A.Uri,D.Bossemeyer
Key ref: D.Lavogina et al. (2009). Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J Med Chem, 52, 308-321. PubMed id: 19143565 DOI: 10.1021/jm800797n
09-Jan-08     Release date:   03-Feb-09    
Go to PROCHECK summary

Protein chain
Pfam   ArchSchema ?
P00517  (KAPCA_BOVIN) -  cAMP-dependent protein kinase catalytic subunit alpha
351 a.a.
341 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     sperm midpiece   11 terms 
  Biological process     regulation of proteasomal protein catabolic process   18 terms 
  Biochemical function     nucleotide binding     13 terms  


DOI no: 10.1021/jm800797n J Med Chem 52:308-321 (2009)
PubMed id: 19143565  
Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases.
D.Lavogina, M.Lust, I.Viil, N.König, G.Raidaru, J.Rogozina, E.Enkvist, A.Uri, D.Bossemeyer.
The crystal structure of a complex of the catalytic subunit (type alpha) of cAMP-dependent protein kinase (PKA C alpha) with ARC-type inhibitor (ARC-1034), the presumed lead scaffold of previously reported adenosine-oligo-arginine conjugate-based (ARC-type) inhibitors, was solved. Structural elements important for interaction with the kinase were established with specifically modified derivatives of the lead compound. On the basis of this knowledge, a new generation of inhibitors, conjugates of adenosine-4'-dehydroxymethyl-4'-carboxylic acid moiety and oligo(D-arginine), was developed with inhibitory constants well into the subnanomolar range. The structural determinants of selectivity of the new compounds were established in assays with ROCK-II and PKBgamma.

Literature references that cite this PDB file's key reference

  PubMed id Reference
20406699 D.Lavogina, C.K.Nickl, E.Enkvist, G.Raidaru, M.Lust, A.Vaasa, A.Uri, and W.R.Dostmann (2010).
Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGIalpha).
  Biochim Biophys Acta, 1804, 1857-1868.  
19774589 D.Lavogina, E.Enkvist, and A.Uri (2010).
Bisubstrate inhibitors of protein kinases: from principle to practical applications.
  ChemMedChem, 5, 23-34.  
19731277 R.Tiwari, and K.Parang (2009).
Protein conjugates of SH3-domain ligands and ATP-competitive inhibitors as bivalent inhibitors of protein kinases.
  Chembiochem, 10, 2445-2448.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.